MedTrace Logo

Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia

NCT00197483 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2005-09-20

No results posted yet for this study

Summary

Dopamine has been closely associated with prefrontal function. The hypothesis that a lower dopaminergic activity is associated with negative symptoms and cognitive dysfunction observed in the patients of schizophrenia is of a heuristic value in guiding research in this area. This hypothesis led us to test whether pergolide, a D1/D2 agonist, could improve negative symptoms and cognitive impairments prevailing in most patients with schizophrenia. This double-blind placebo controlled study will investigate the remedial effect of pergolide on negative symptoms and cognitive impairments in schizophrenia.

Conditions

Interventions

DRUG

Pergolide (drug)

Sponsors & Collaborators

  • Hamamatsu University

    lead OTHER

Principal Investigators

  • Norio Mori, Ph.D · Hamamatsu University, School of Medicine, Department of Psychiatry and Neurology

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00197483 on ClinicalTrials.gov